VIP-targeted cytotoxic nanomedicine for breast cancer

Drug Delivery and Translational Research

Volumn 2, Issue 6, 2012, Pages 454-462

  Dagar, Aparna ^a,d   Kuzmis, Antonina ^a   Rubinstein, Israel ^a,c   Sekosan, Marin ^a,e   Onyuksel, Hayat ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

^d Fresenius Kabi USA   (United States)

^e Jr Hospital   (United States)

Author keywords

Breast cancer; Human vasoactive intestinal peptide; MNU induced breast cancer; Paclitaxel; Phospholipid mixed micelles; Targeted drug delivery

Indexed keywords

CREMOPHOR; PACLITAXEL; PHOSPHOLIPID; STERICALLY STABILIZED MIXED MICELLE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VIVONEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE MARROW; BREAST ADENOCARCINOMA; BREAST TUMOR; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; ENTHALPY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDRODYNAMICS; HYPOTENSION; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TUMOR VOLUME;

EID: 84869000989     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0107-x     Document Type: Article

References (48)

1. Singh S, Dash AK. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. Crit Rev Ther Drug Carrier Syst. 2009; 26(4): 333-72.
2. Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012.
3. Banerjee A, Onyuksel H. Human pancreatic polypeptide in a phospholipid-based micellar formulation. Pharm Res. 2012; 29(6): 1698-711.
4. Koo OM, Rubinstein I, Onyuksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res. 2011; 28(4): 776-87.
5. Onyuksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm. 2009; 365(1-2): 157-61.
6. Cesur H, Rubinstein I, Pai A, Onyuksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine. 2009; 5(2): 178-83.
7. Krishnadas A, Rubinstein I, Önyüksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res. 2003; 20(2): 297-302.
8. Ashok B, Arleth L, Hjelm RP, Rubinstein I, Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci. 2004; 93(10): 2476-87.
9. Kuzmis A, Lim SB, Desai E, Jeon E, Lee BS, Rubinstein I, et al. Micellar nanomedicine of human neuropeptide Y. Nanomedicine. 2011; 4(7): 464-71.
10. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011; 63(3): 136-51.
11. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 2012; 503: 255-68.
12. Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release. 2003; 91(1-2): 123-33.
13. Zhang XX, Eden HS, Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release. 2012; 159(1): 2-13.
14. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010; 27(7): 286-98.
15. Reubi JC. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci. 2000; 921: 1-25.
16. Ortner A, Wernig K, Kaisler R, Edetsberger M, Hajos F, Kohler G, et al. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles. J Drug Target. 2010; 18(6): 457-67.
17. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000; 60(11): 3105-12.
18. Schulz S, Rocken C, Mawrin C, Weise W, Hollt V, Schulz S. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin Cancer Res. 2004; 10(24): 8235-42.
19. Dagar S, Sekosan M, Rubinstein I, Onyuksel H. Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast Cancer Res Treat. 2001; 65(1): 49-54.
20. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med. 1995; 36(10): 1846-53.
21. Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002; 29(7): 855-62.
22. Raderer M, Kurtaran A, Yang Q, Meghdadi S, Vorbeck F, Hejna M, et al. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med. 1998; 39(9): 1570-5.
23. Rubinstein I, Soos I, Onyuksel H. Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Chem Biol Interact. 2008; 171(2): 190-4.
24. Onyuksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009; 274(2): 327-30.
25. Fahrenkrug J, Hannibal J, Tams J, Georg B. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab. 2000; 20(8): 1205-14.
26. Dagar S, Sekosan M, Lee BS, Rubinstein I, Onyuksel H. VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. J Control Release. 2001; 74(1-3): 129-34.
27. Sou K, Endo T, Takeoka S, Tsuchida E. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug Chem. 2000; 11(3): 372-9.
28. Seelig J. Titration calorimetry of lipid-peptide interactions. Biochim Biophys Acta. 1997; 1331(1): 103-16.
29. Zuidam NJ, de Vruch R., Crommelin D. J. A. Characterization of liposomes. In: Torchilin VP, Weissig V., editors. Liposomes. 2nd ed. Oxford: Oxford University Press; 2003. p. 31.
30. Moody TW, Jensen RT. Breast cancer VPAC1 receptors. Ann N Y Acad Sci. 2006; 1070: 436-9.
31. Moon RC, Constantinou AI. Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res Treat. 1997; 46(2-3): 181-9.
32. Arleth L, Ashok B, Onyuksel H, Thiyagarajan P, Jacob J, Hjelm RP. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir. 2005; 21(8): 3279-90.
33. Couvineau A, Tan YV, Ceraudo E, Lacapere JJ, Murail S, Neumann JM, et al. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling. Ann N Y Acad Sci. 2006; 1070: 205-9.
34. Bhunia A, Domadia PN, Bhattacharjya S. Structural and thermodynamic analyses of the interaction between melittin and lipopolysaccharide. Biochim Biophys Acta. 2007; 1768(12): 3282-91.
35. Schote U, Ganz P, Fahr A, Seelig J. Interactions of cyclosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry. J Pharm Sci. 2002; 91(3): 856-67.
36. Hagiwara H, Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer. 2004; 11(1): 82-5.
37. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008; 69(1): 1-9.
38. Spratlin J, Sawyer MB. Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol. 2007; 61(3): 222-9.
39. Wang Y, Li X, Wang L, Xu Y, Cheng X, Wei P. Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomed. 2011; 6: 1497-507.
40. Fetterly GJ, Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci. 2003; 5(4): E32.
41. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012; 14(2): 282-95.
42. Tsubura A, Lai YC, Miki H, Sasaki T, Uehara N, Yuri T, et al. Review: animal models of N-Methyl-N-nitrosourea-induced mammary cancer and retinal degeneration with special emphasis on therapeutic trials. In Vivo. 2011; 25(1): 11-22.
43. Nowfar S, Teplitzky SR, Melancon K, Kiefer TL, Cheng Q, Dwived PD, et al. Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin. Breast Cancer Res Treat. 2002; 72(1): 33-43.
44. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994; 331(17): 1116-21.
45. Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs. 2008; 9(12): 1277-86.
46. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006; 121(2): 159-76.
47. Rubinstein I, Ashok B, Tsueshita T, Onyuksel H. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo. Peptides. 2005; 26(3): 509-15.
48. Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother. 2011; 23(2): 59-66.